中高危局限性前列腺癌根治性治疗中的种族差异:机构特征与社会经济因素的影响
基于美国国家癌症数据库2004年1月至2013年12月确诊的223 873例白人和59 262例黑人≥40岁活检证实中高危局限性前列腺癌患者,分析根治性治疗接受率的种族差异。83%白人接受根治性治疗 vs 74%黑人;39%的治疗机构白人根治性治疗率显著更高,仅1%机构黑人更高。校正社会人口学和临床因素后,多数机构倾向于对白人实施根治性治疗。
要点
- 2004-2013年白人根治性治疗率83%(n=185 647)vs 黑人74%(n=43 662)。
- 39%机构白人根治性治疗率显著更高,仅1%机构黑人更高。
- 白人根治性治疗率从81%升至83%(p<0.001),黑人从73%升至75%(p=0.001)。
核心结论
- 校正社会人口学和临床因素后,多数机构倾向于对白人实施根治性治疗。
- 医疗服务提供者在为局限性前列腺癌患者咨询治疗方案时应意识到这些固有偏倚。
研究设计与样本
- 利用美国国家癌症数据库的回顾性队列研究,纳入2004年1月至2013年12月确诊的活检证实中高危局限性前列腺癌患者,包括223 873例白人男性和59 262例黑人男性,年龄≥40岁。
- 采用多水平逻辑回归预测接受前列腺癌根治性治疗的比值比,并进行敏感性和亚组分析以校正患者和机构层面的固有差异。
主要发现
- 2004年至2013年间,83%(n=185 647)白人男性接受根治性治疗,黑人男性为74%(n=43 662)。
- 该期间白人男性根治性治疗率从81%升至83%(p<0.001),黑人男性从73%升至75%(p=0.001)。
- 39%的治疗机构白人男性根治性治疗率显著更高,仅1%的机构黑人男性更高。
临床怎么用
- 医疗服务提供者在为局限性前列腺癌患者咨询治疗方案时应意识到这些固有偏倚。
- 非临床因素如治疗机构类型和地点影响治疗率。
局限性
- 研究受潜在选择偏倚和效应修饰限制。
- 研究受队列回顾性性质的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The gap in prostate cancer (PCa) survival between Blacks and Whites has widened over the past decade. Investigators hypothesize that this disparity may be partially attributable to differences in rates of definitive therapy between races. OBJECTIVE: To examine facility level variation in the use of definitive therapy among Black and White men for localized PCa. DESIGN, SETTING, AND PARTICIPANTS: Using data from the National Cancer Data Base, we identified 223 873 White and 59 262 Black men ≥40 yr of age receiving care within the USA with biopsy confirmed localized intermediate/high-risk PCa diagnosed between January 2004 and December 2013. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multilevel logistic regression was fitted to predict the odds of receiving definitive therapy for PCa. Sensitivity and subgroup analyses were performed to adjust for inherent patient and facility-level differences when appropriate. RESULTS AND LIMITATIONS: Eighty-three percent (n=185 647) of White men received definitive therapy compared with 74% (n=43 662) of Black men between 2004 and 2013. Overall rates of definitive therapy during that time increased for both White (81% vs 83%, p<0.001) and Black (73% vs 75%, p=0.001) men. However, 39% of treating facilities demonstrated significantly higher rates of definitive therapy in White men, compared with just 1% favoring Black men. Our study is limited by potential selection bias and effect modification. CONCLUSIONS: After adjusting for sociodemographic and clinical factors, we found that most facilities favored definitive therapy in Whites. Health care providers should be aware of these inherit biases when counseling patients on treatment options for localized PCa. Our study is limited by the retrospective nature of the cohort. PATIENT SUMMARY: We found significant differences in rates of radiation and surgical treatment for prostate cancer among White and Black men, with most facilities favoring Whites. Nonclinical factors such as treatment facility type and location influenced rates of therapy.
引用
- Friedlander DF, Trinh QD, Krasnova A, et al. Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2017. PMID: 28778619. doi:10.1016/j.eururo.2017.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。